- The Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF) approved the Philippines participation in the clinical trials of COVID-19 vaccine
- The Philippines will collaborate with several Chinese research institutions
- Part of the DOST’s proposal includes the establishment of the Virology S&T Institute in New Clark City in Pampanga
In a historic move, the Philippines will soon participate in several global clinical trials in the development of a vaccine against the novel coronavirus or SARS-CoV-2.
The Inter-Agency Task Force for the Management of Emerging Infectious Dis
eases (IATF) approved the Department of Science and Technology’s (DOST) recommendation that the Philippines participate in the COVID-19 vaccines’ clinical trials.
IATF signed Resolution No. 39 series of 2020 which confirmed the collaboration of the Philippines with the Chinese Academy of Science in Guangzhou Institute of Health, SinoPharma in Wuhan Institute of Biological Products, and Beijing Institute for the COVID-19 vaccine clinical trials.
Under the resolution, the Philippines will also collaborate with Taiwanese vaccine manufacturers Adimmune Corporation and Academia Sinica for clinical trials of another vaccine.
According to IATF, the collaborating teams will be provided with “the World Health Organization requirements for COVID-19 vaccine target product profile; Pre-qualification process for WHO approvals; Philippine Food and Drug Administration to update guidelines on clinical trials.”
“Pursuant to the foregoing, the FDA is directed to advise on the process to facilitate the issuance of a permit for the conduct of the clinical trial in the Philippines,” the IATF-EID’s resolution stated.
Under the resolution, the DOST suggested the creation of research centers in the country that will strengthen local vaccine development.
Part of the proposal includes the establishment of the Virology S&T Institute in New Clark City in Pampanga and the “reactivation” of the Pharmaceutical Development Unit at the DOST Industrial Technology Development Institute.